포인트 오브 케어(POC) 의료 소프트웨어 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the point-of-Care medical software market size is expected to grow from USD 4.95 billion in 2025 to USD 5.74 billion in 2026 and is forecast to reach USD 12.77 billion by 2031 at 17.33% CAGR over 2026-2031.

This report is Segmented by Component (Software Platform, Middleware, Services), Deployment Mode (On-Premise, Cloud-Based, Hybrid), End User (Hospitals & Critical Care, Diagnostic Centers, Home Care), Application (Glucose Monitoring, Cardiometabolic Monitoring, Hematology), and Geography (North America, Europe, Asia-Pacific, South America).

Global Point-of-Care Medical Software Market Trends and Insights

Cloud Migration for Distributed Point-of-Care Workflows

Cloud adoption in the point-of-care medical software market has moved beyond early adopters and is gaining traction among hospital networks that previously depended on local middleware. The main attraction is operational, because cloud-hosted platforms can push software updates, renew operator credentials, and track cross-site quality trends without requiring technical support at every testing location. This matters most when a health system runs POCT programs across clinics, physician offices, ambulatory centers, and hospital departments that share the same governance requirements but do not share the same IT staffing depth. In January 2026, WellSpan Health announced a broad migration of its technology portfolio to AWS, with scalability for AI integration highlighted as a key rationale, which supports the direction of travel toward cloud-native clinical software environments. As EMR vendors continue to modernize their architectures, the point-of-care medical software market is placing more value on platforms that can sit inside a larger cloud data layer instead of serving only as a narrow laboratory compliance utility.

Interoperability Requirements Across LIS, EMR, and POCT Devices

Interoperability is becoming a purchasing filter in the point-of-care medical software market because hospitals want device data to move cleanly across LIS, EMR, and remote care workflows. The January 2027 CMS-0057-F timeline is especially important in the United States because it requires specified workflows to support FHIR R4 APIs, which many legacy stacks cannot deliver without major redesign work. A 2024 study on Hospital@Home workflows showed that combining cloud infrastructure with HL7 FHIR enables point-of-care results to flow across several stakeholder systems at the same time, which is a capability older implementations do not support as effectively. That is giving open, vendor-neutral middleware an advantage when provider organizations compare long-term integration options across mixed device environments. The point-of-care medical software market is therefore rewarding platforms that support current messaging standards while preserving backward compatibility with installed device fleets and existing laboratory workflows.

High Deployment, Validation, and Integration Costs

The point-of-care medical software market still faces a hard economic barrier because enterprise rollouts cost much more than middleware license fees alone suggest. Health systems must pay for LIS integration work, site-by-site workflow validation, device interface qualification, user training, and recurring support contracts that expand with every instrument type and location. Those costs rise quickly when a provider network uses several device brands, because each interface adds separate development and testing work before the platform can run at scale. CLSI guidance on POCT communications underlines how multi-vendor environments create recurring interface overhead, which helps explain why project teams often underestimate total implementation effort CLSI.ORG. That cost burden slows purchasing decisions in the point-of-care medical software market and tends to favor vendors with larger prebuilt interface libraries and stronger implementation service capabilities.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Remote and Home-Based Point-of-Care Testing
2. AI-Enabled Analytics for Antimicrobial Stewardship and Quality Control
3. Legacy Device Fragmentation and Vendor Lock-In

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software platforms accounted for 64.8% of the point-of-care medical software market size in 2025 and are projected to grow at a 17.2% CAGR through 2031. That alignment between leading share and fastest growth shows that providers still see the platform layer as the core control point for operator management, quality workflows, utilization tracking, and downstream data routing. In the point-of-care medical software market, these functions matter because hospitals are not only buying a data viewer, they are buying a governance system that must standardize decentralized testing activity across many departments and sites. Middleware remains strategically important because it sits between older device interfaces and newer interoperability demands, which makes it central to health systems preparing for API-led connectivity requirements. Services form the smallest component, but they retain steady relevance because validation, training, deployment support, and compliance preparation are getting harder for internal teams to absorb on their own.

The second effect of platform dominance is competitive, because incumbent vendors can use their installed base to sell adjacent modules such as analytics, predictive quality tools, and extra connectivity tiers. Siemens Healthineers released UniPOC version 1.9 in June 2025, and the platform remained notable for automated operator validation and recertification workflows together with regular device interface updates. The same product was also referenced in U.S. government technology documentation in late 2025, which reinforces the staying power of established enterprise footprints once a platform is embedded in regulated care settings. FDA's Quality Management System Regulation took effect on February 2, 2026 and brought ISO 13485 concepts more directly into U.S. device quality controls, adding another layer of scrutiny around software design, documentation, and cybersecurity readiness. In the point of care medical software industry, that raises the barrier for smaller challengers that may offer new features but lack the audit history, documentation discipline, and long-cycle customer relationships that large platforms already possess.

Cloud-based deployment held 56.4% share in 2025 and is also the fastest-growing deployment model with an 18.4% CAGR through 2031. The point-of-care medical software market favors cloud options because they let providers push security patches, device drivers, and regulatory updates across distributed testing locations without waiting for on-site intervention. This is especially valuable when the testing network includes outpatient facilities and satellite sites that run important POCT volumes but have thin local IT support. A 2024 Hospital@Home study showed that cloud architecture combined with HL7 FHIR can support real-time result exchange across multiple stakeholder systems, which supports the practical value of cloud-hosted models in distributed care environments. On-premise deployments still matter in facilities with stricter data-sovereignty expectations and in government or military environments where external routing controls remain tight.

Hybrid deployment is emerging as the migration route for large provider systems that cannot replace older middleware in a single capital cycle. In the point-of-care medical software market, this model lets the cloud handle API translation and remote administration while keeping certain device-to-LIS flows inside local infrastructure. That approach fits organizations that need partial interoperability progress before 2027 but still have a meaningful installed base of on-premise systems. It also introduces extra governance work, because auditors and internal teams must validate both the cloud layer and the local layer against the same quality and compliance expectations. As a result, the point of care medical software industry is seeing hybrid win bids as a practical bridge, even while cloud continues to take the leading role in new deployments.

Complete Report Scope:

• By Component
  • Software
  • Hardware
  • Services
• By Application
  • In Vivo Diagnostics
  • In Vitro Diagnostics
• By Deployment Mode
  • Cloud Based
  • Hybrid
  • On Premises
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Diagnostic Laboratories
  • Clinics and Other Healthcare Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.1% of the point-of-care medical software market share in 2025, making it the largest regional contributor. The United States drove most of that position because it combines high POCT test density, mature reimbursement systems, and active hospital IT modernization. The region is also moving faster on replacement cycles because providers must prepare for FHIR R4 interoperability obligations under CMS-0057-F by January 2027, while also responding to tighter cybersecurity expectations under the HIPAA Security Rule proposal CMS. Canada adds a smaller but growing contribution as provincial networks use cloud tools to manage distributed POCT programs across remote care settings. In the United States, the point-of-care medical software market also benefits from value-based care incentives, with Humana reporting 13.4% fewer emergency department visits among value-based care Medicare Advantage members than comparable non-value-based-care members.

Europe remained the second-largest region in the point-of-care medical software market, with demand centered on Germany, the United Kingdom, France, Italy, and Spain. Germany and the United Kingdom stand out for stronger digital hospital adoption and structured laboratory reporting requirements, which make POCT software governance more important in procurement discussions. France and Italy are also moving forward through public hospital modernization programs, while Spain remains more fragmented because regional health systems shape purchasing patterns more than a single national buying structure. Across the region, the point-of-care medical software market continues to face slower adoption than North America where reimbursement remains more fragmented and where multi-country provider groups must manage different local operating conditions.

Asia Pacific is the fastest-growing region and is projected to expand at a 34.5% CAGR between 2026 and 2031. The point-of-care medical software market is gaining momentum there because healthcare digitization spending is rising, provider networks are broadening beyond major urban hospitals, and connected care programs are pulling more testing activity into decentralized settings. Demand is strongest where software can support geographically dispersed facilities without a large on-site IT footprint, which makes cloud-hosted dashboards and remote administration especially relevant. South Korea and Australia add premium demand from hospital systems that place a high value on quality documentation and structured data exchange. South America and the Middle East and Africa remain smaller today, but the point-of-care medical software market has long-term room to expand there as private hospital groups, diagnostic chains, and wider healthcare IT investment continue to build out the underlying infrastructure.

List of Companies Covered in this Report:

1. Alphabet Inc. (Google Health / DeepMind)
2. Microsoft
3. NVIDIA
4. Siemens Healthineers
5. GE HealthCare Technologies Inc.
6. Koninklijke Philips
7. Roche
8. Tempus AI, Inc.
9. Aidoc Medical Ltd.
10. Qure.ai Technologies Private Limited
11. Heartflow
12. PathAI, Inc.
13. Paige.AI, Inc.
14. Ada Health GmbH
15. AliveCor
16. Butterfly Network, Inc.
17. Digital Diagnostics
18. Lunit
19. Ibex Medical Analytics Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Faster Triage and Early Disease Detection
  • 4.2.2 Expansion of AI-Enabled Radiology and Pathology Workflows
  • 4.2.3 Multi-Modal Clinical Data Convergence Improves Diagnostic Confidence
  • 4.2.4 Provider Push Toward Workflow Automation in Overburdened Health Systems
  • 4.2.5 Integration With Wearables and Remote Monitoring Expands Diagnostic Reach
  • 4.2.6 Growing Investment in Clinical Validation and Interoperable AI Platforms
• 4.3 Market Restraints
  • 4.3.1 Algorithm Explainability and Liability Concerns Slow Clinical Trust
  • 4.3.2 High Integration Cost Across PACS, EHR, and Hospital IT Stacks
  • 4.3.3 Data Privacy, Sovereignty, and Cross-Border Model Training Constraints
  • 4.3.4 Regulatory Heterogeneity and Revalidation Burden for Model Updates
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts (Value; volume for key analytes)

• 5.1 By Component
  • 5.1.1 Software
  • 5.1.2 Hardware
  • 5.1.3 Services
• 5.2 By Application
  • 5.2.1 In Vivo Diagnostics
  • 5.2.2 In Vitro Diagnostics
• 5.3 By Deployment Mode
  • 5.3.1 Cloud Based
  • 5.3.2 Hybrid
  • 5.3.3 On Premises
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Diagnostic Laboratories
  • 5.4.4 Clinics and Other Healthcare Providers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Alphabet Inc. (Google Health / DeepMind)
  • 6.3.2 Microsoft Corporation
  • 6.3.3 NVIDIA Corporation
  • 6.3.4 Siemens Healthineers AG
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Koninklijke Philips N.V.
  • 6.3.7 F. Hoffmann-La Roche Ltd
  • 6.3.8 Tempus AI, Inc.
  • 6.3.9 Aidoc Medical Ltd.
  • 6.3.10 Qure.ai Technologies Private Limited
  • 6.3.11 Heartflow, Inc.
  • 6.3.12 PathAI, Inc.
  • 6.3.13 Paige.AI, Inc.
  • 6.3.14 Ada Health GmbH
  • 6.3.15 AliveCor, Inc.
  • 6.3.16 Butterfly Network, Inc.
  • 6.3.17 Digital Diagnostics, Inc.
  • 6.3.18 Lunit Inc.
  • 6.3.19 Ibex Medical Analytics Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White Space and Unmet Need Assessment